- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BIOSERGEN AB: Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial | 4 | Cision News | ||
| 05.12. | BIOSERGEN AB: Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 2 | Cision News | ||
| 03.12. | Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 1 | Cision News | ||
| 03.12. | Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3 | 1 | Cision News | ||
| 26.11. | BIOSERGEN AB: Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections | 1 | Cision News | ||
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 26.11. | The last day of trading with the warrants of series TO3 in Biosergen AB is today, November 26, 2024 | 1 | Cision News | ||
| 21.11. | BIOSERGEN AB: Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005 | 1 | Cision News | ||
| 18.11. | BIOSERGEN AB: Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million | 1 | Cision News | ||
| 18.11. | The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49 | 1 | Cision News | ||
| 13.11. | BIOSERGEN AB: Biosergen discusses positive results in patients with deadly fungal infections | 2 | Cision News | ||
| 08.11. | Biosergen AB: Biosergen publishes interim report for third quarter 2024 | 62 | GlobeNewswire (Europe) | Friday November 8, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the... ► Artikel lesen | |
| 07.11. | BIOSERGEN AB: Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial | 1 | Cision News | ||
| 06.11. | BIOSERGEN AB: Biosergen's CEO: "I'm optimistic that we may cure patients" | 2 | Cision News | ||
| 31.10. | BIOSERGEN AB: Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections | 1 | Cision News | ||
| 18.10. | BIOSERGEN AB: Biosergen advances BSG005 antifungal drug candidate trial | 1 | Cision News | ||
| 07.10. | Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial | 87 | GlobeNewswire (Europe) | October 7, 2024 - Biosergen AB ("Biosergen"), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first... ► Artikel lesen | |
| 06.09. | BIOSERGEN AB: Biosergen's CEO: "The first patient regained his health" | 1 | Cision News | ||
| 05.09. | Biosergen - Optimism after treatment success - Mangold Insight Analysis | 1 | Cision News | ||
| 30.08. | Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005 | 2 | GlobeNewswire (USA) | ||
| 30.08. | BIOSERGEN AB: Biosergen publishes interim report for second quarter 2024 | 1 | Cision News |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Sartorius, Qiagen, Siemens Energy, DHL Group, Adidas, Puma: DAX-Ausblick | Nach seiner jüngsten Rekordjagd hat der DAX in der abgelaufenen Woche etwas Luft geholt. Unter dem Strich legte das größte deutsche Börsenbarometer trotzdem 21 Punkte zu und schloss mit knapp 20.406... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec Aktie: 50 Prozent hoch oder Ende der Rallye-Träume? | Die Evotec Aktie schloss die vergangene Woche mit einem deutlichen Verlust ab: Fast fünf Prozent Minus am Freitag auf 8,275 Euro zeigen, dass der Druck auf die Biotech-Aktie zunahm. Besonders brisant... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
Das Unternehmen BIOSERGEN AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +11,27 % bei einem Aktienkurs von 0,045 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.
